SVA — Sernova Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$53.00m
- CA$57.51m
Annual cashflow statement for Sernova Biotherapeutics, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.97 | -24.4 | -39 | -32.2 | -15.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.687 | 6.61 | 3.23 | 1.6 | 2.83 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.542 | 2.95 | 4.99 | 11.2 | 1.74 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -6.84 | -14.4 | -30.3 | -18.9 | -10.9 |
| Capital Expenditures | -0.017 | -0.329 | -0.099 | 0 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.212 | -46 | 34.9 | 11.1 | 0.025 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.229 | -46.3 | 34.8 | 11.1 | 0.025 |
| Financing Cash Flow Items | 1.12 | 0.323 | 0.675 | 0.261 | 0.065 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 31 | 36.7 | 0.503 | 5.07 | 5.14 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 23.9 | -24.1 | 4.95 | -2.71 | -5.75 |